GS-1720

DRUG3 trials

Sponsors

Gilead Sciences Inc., Gilead Sciences

Conditions

HIV-1 InfectionHIV-1-infection

Phase 1

Study of Novel Antiretrovirals in Participants With HIV-1

CompletedNCT05585307

Gilead SciencesHIV-1-infection

Start: 2022-10-26End: 2024-03-18Updated: 2025-05-08

Phase 2

An Operationally Seamless Phase 2/3, Randomized, Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination with GS-4182 Versus Biktarvy in Treatment Naive People with HIV-1

SuspendedCTIS2024-512505-66-00

Gilead Sciences Inc.HIV-1 Infection

Start: 2025-03-03Target: 186Updated: 2025-10-29

An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1

Not yet recruitingCTIS2024-511054-50-00

Gilead Sciences Inc.HIV-1 Infection

Target: 35Updated: 2025-04-02